Healthcare
Neuronetics, Inc.(STIM)
Live Price
Offline$1.23
+1.65% today
Window Change
-20.13%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $140.00M
- Revenue Growth
- +99.2%
- EPS Growth
- +57.2%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neuronetics, Inc. (STIM) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $1.23 and down 20.1% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +99.2%, EPS growth of +57.2%, a dividend yield of 0.0%. What stands out right now is revenue +99.2%, EPS +57.2%, free cash flow +34.8% with operating margin -21.1% and ROIC -27.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STIM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+99.2% vs +7.6% peer median
Operating Margin
Below sector median
-21.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +99.2% and EPS at +57.2%, with operating margin around -21.1%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STIM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STIM Max Drawdown
-28.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STIM and SPY.
Company Overview
Neuronetics, Inc.
NASDAQ Global Market
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
- Leadership
- Daniel L. Reuvers
- IPO Date
- Jun 28, 2018
- Employees
- 716
- Street Address
- 3222 Phoenixville Pike
- Mailing
- Malvern, PA, 19355
- Region
- Malvern, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 640 4202
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.9
- Price/Book
- 6.2
Growth
- Revenue
- +99.2%
- EPS
- +57.2%
- Free Cash Flow
- +34.8%
Profitability
- Gross Margin
- 48.5%
- Operating Margin
- -21.1%
- Net Margin
- -26.1%
- ROE
- -138.9%
- ROIC
- -27.0%
Balance Sheet
- Debt/Equity
- 4.04
- Current Ratio
- 2.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.